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Abstract
Chronic obstructive pulmonary disease (COPD) phenotyping can help define clusters of patients with common characteristics that relate to clinically meaningful outcomes. In this review, we describe 7 clinically meaningful COPD phenotypes that can be identified by primary care physicians as well as specialists and that have specific management and prognostic implications: (1) asthma-COPD overlap phenotype, (2) frequent exacerbator phenotype, (3) upper lobeepredominant emphysema phenotype, (4) rapid decliner phenotype, (5) comorbid COPD phenotype, (6) physical frailty phenotype, and (7) In this concise review, we chose to address 7 COPD phenotypes that can help individualize care. These are chosen based on implications regarding outcomes and day-to-day management, and not defined by delineation along anatomic, physiologic, or pathologic schema ( Figure 1) . Therefore, an overlap between phenotypes is expected and is likely the natural norm, and inclusion into one phenotype is not to the exclusion of the others. Although the asthma-COPD overlap phenotype, the frequent exacerbator phenotype, and the upper lobeepredominant emphysema phenotypes are well established in the COPD literature, the rapid decliner and comorbid phenotypes have been defined via cluster analysis. 4 Physical frailty and emotional frailty traits, although not well defined in patients with COPD, have long been recognized as having direct and independent therapeutic implications for management, in addition to substantially impacting quality of life, prognosis, and health care utilization (Table) .
ASTHMA-COPD OVERLAP PHENOTYPE
Asthma and COPD are regarded as separate conditions with differing underlying pathophysiology. Although their individual clinical presentations may be "typical" and easily recognizable, in many patients, especially older people and smokers, determination of the etiology of chronic respiratory symptoms and airflow limitation as originating from asthma, smoking-related COPD, or both can be challenging. 5 The hallmark of the asthma-COPD overlap phenotype is the coexistence of increased variability of airflow in a patient with incompletely reversible airway obstruction. Based on the definition used and the population under study, the prevalence of the asthma-COPD overlap phenotype in patients with COPD has been reported to range from 12% to 55%. 6 The attempt to define this overlap of phenotypes was prompted by an association with a higher symptom burden, poorer outcomes (including more frequent and severe exacerbations), and diagnostic and therapeutic uncertainties, because this set of patients was excluded from clinical trials that used strict definitions to identify patients with COPD or asthma. 5, [7] [8] [9] [10] The entity itself and its definition remain controversial because of a lack of broad consensus. However, until such time that obstructive airway diseases, including COPD and asthma, are categorized on the basis of genotypes and endotypes, identifying patients with this overlap retains clinical utility in choosing pharmacological therapy.
In 2012, a consensus-based guideline proposed that the diagnosis of the "overlap phenotype COPD-asthma" be made when 2 major criteria or 1 major and 2 minor criteria are met. The major criteria are (1) a very positive bronchodilator test result (increase in forced expiratory volume in the first second of expiration [FEV 1 ] of 15% of predicted and 400 mL), and (2) sputum eosinophilia and personal history of asthma. The minor criteria are (1) high total IgE level, and (2) personal history of atopy and positive bronchodilator test result (increase in FEV 1 of 12% of predicted and 200 mL) on 2 or more occasions. 11 To aid further research efforts in patients with overlap, a 2015 joint Global Initiative for AsthmaeGOLD "description," instead of a "definition," of asthma-COPD overlap syndrome was put forth in the form of features that are likely to identify this entity. 12 The age at which features of the overlap phenotype manifest also appears to be important. Patients with onset of asthma-COPD overlap after age 40 years (likely stemming predominantly from COPD with later onset of asthmalike features) seem to do worse compared with those who have the onset of asthma-COPD overlap before age 40 (likely stemming from asthma) regarding lung function decline, health care utilization, and mortality. 9 In cases in which a diagnosis of asthma is being entertained but questioned, features such as a high exhaled nitric oxide concentration, peripheral blood or sputum eosinophilia, and other evidence of atopy may help identify patients who would benefit from the early institution and continuation of inhaled corticosteroids. 10 
Practical Implications
In patients with asthma-COPD overlap phenotype, therapy with inhaled corticosteroids should be strongly considered in addition to long-acting bronchodilators.
FREQUENT EXACERBATOR PHENOTYPE
Exacerbations of COPD are defined by the GOLD as acute events characterized by a worsening of the patient's respiratory symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation and leads to a change in medication. 3 A widely accepted criterion for the frequent exacerbator phenotype is the occurrence of 2 or more exacerbations per year. 13 The proportion of patients defined and reported as frequent exacerbators has ranged from 13% to 47% based on the populations studied, with the proportion increasing as the severity of airflow obstruction increases. 13 The impact of frequent exacerbations is substantialdincreased risk of depressive symptoms, decline in lung function, poorer quality of life, decreased physical activity, increased health care utilization, and up to a 3-fold increase in mortality.
14 Of factors associated with frequent exacerbations, the most utilitarian in identifying this cohort appear to be a history of previous exacerbations and anxiety, the latter of which has been associated independently with very frequent exacerbations. 15, 16 Long-acting inhaled anticholinergics and b-agonists alone and in combination with each other have been reported to reduce exacerbation frequency in COPD with moderate or worse airflow obstruction. 17, 18 The triple combinations of tiotropium-fluticasone-salmeterol and tiotropium-budesonide-formoterol also appear to be effective in reducing moderate to severe exacerbations, but the corticosteroid-containing inhalers may confer an increased risk of pneumonia. 18 Oral acetylcysteine added to an optimized inhaled medication regimen has been reported to reduce the frequency of COPD exacerbations. 17, 19 Macrolides for prevention of exacerbations have the most supporting data, although other antibiotics have also been studied; these agents can reduce the frequency of exacerbations and hospitalizations and increase the time between exacerbations. 17, 20, 21 Roflumilast, an anti-inflammatory phosphodiesterase type 4 inhibitor, has proven most beneficial in exacerbation prevention in a subset of patients older than 40 years with severe to very severe COPD, a history of chronic bronchitis, and frequent exacerbations. Although drug tolerance has been an issue because of minor adverse effects, it has documented efficacy in improving baseline lung function and reducing severe exacerbations and hospitalizations even in the setting of baseline use of long-acting bronchodilator(s) and inhaled corticosteroids. 17, 22 Practical Implications The addition of anti-inflammatory medication (antibiotics or phosphodiesterase type 4 inhibitors) and/or acetylcysteine for exacerbation prevention may be a valuable and In the early 2000s, the landmark National Emphysema Treatment Trial found that in a carefully selected group of patients with upper lobeepredominant emphysema, surgical LVR led to durable improvement in exercise capacity, symptoms, and oxygen use. 23 Surgical LVR may be considered a palliative procedure that improves exercise capacity and symptoms and is associated with a potential survival advantage in a subset of patients. Based on data from the National Emphysema Treatment Trial, good candidates for surgical LVR are patients who have advanced upper lobeepredominant emphysema with air trapping, an FEV 1 of less than 45% of predicted, and a diffusing capacity of the lung for carbon monoxide of more than 20% of predicted. Also, candidates must have quit smoking, be able to participate in pulmonary rehabilitation before and after the procedure, and be acceptable from a surgical risk standpoint. 23 Surgical LVR is a safe procedure with substantial benefits when performed in carefully selected patients at experienced centers. Results of nonsurgical LVR techniques attempted through bronchial valves, intrabronchial coils, and steam-induced thermal injury have been mixed and are not yet approved for clinical use in the United States.
Clinical Implications
Surgical LVR should be considered in patients with severe symptoms despite maximal therapy and upper lobeepredominant emphysema.
RAPID DECLINER PHENOTYPE
Cluster phenotyping of patients with COPD has identified a cohort of relatively younger patients without major cardiovascular comorbidities who appear to have a faster decline in lung function, poor nutritional and overall health status, and high mortality rate. 4 Although the pathogenesis of this rapid decliner phenotype is unclear at this time, physicians should be cognizant of this important subset of patients so they can be targeted for early referral to specialized centers for aggressive disease management and potentially lung transplant.
Practical Implications
Patients with COPD who appear to have a rapid decline in lung function and poor nutritional status may constitute a subgroup of patients with high mortality and should be referred for evaluation and aggressive disease management, including lung transplant.
COMORBID PHENOTYPE
The comorbid phenotype refers to older patients with moderate respiratory disease and a substantial comorbidity burden. Cluster analyses have identified groups of patients with "systemic COPD" characterized by a high body mass index and very high rates of diabetes, congestive heart failure, and ischemic heart disease. Interestingly, these patients had higher levels of dyspnea, poorer quality of life, increased health care utilization, and increased mortality risk compared with patients who had comparable airflow limitation but without a major comorbidity burden. 4 Two independent reports suggest that the poor health outcomes and quality of life scores in this phenotype are likely predominantly determined by cardiovascular comorbidities. 4, 24 Comorbidities appear to be stronger determinants of quality of life than degree of airflow obstruction in patients with mild to moderate airflow limitation; however, the opposite holds true with more severe impairment in lung function. However, the level of airflow obstruction contributes more to impaired quality of life when lung function is severely compromised. 24 
Practical Implications
In patients with persistently symptomatic COPD who are receiving optimal respiratory therapy and have a considerable comorbidity burden of cardiovascular and metabolic disease, targeting aggressive management of comorbidities may help improve symptoms and health outcomes.
PHYSICAL FRAILTY PHENOTYPE
Frailty is a multidimensional syndrome characterized by loss of physiologic and cognitive reserve that has prognostic importance. It is a common geriatric syndrome but does not correlate with age only. The most commonly utilized models of frailty are the Fried frailty phenotype that is defined by meeting 3 or more of 5 criteria (weakness, slowness, low level of physical activity, self-reported exhaustion, and unintentional weight loss) and the frailty deficit index (measured by cumulative deficits identified in a comprehensive geriatric assessment). Frailty and respiratory impairment have a strong association that has been best explored in COPD. Frailty may be prevalent in as many as a half of patients with COPD, especially elderly patients, is strongly associated with worse airflow limitation, symptoms, and exacerbation frequency, and can be mitigated through pulmonary rehabilitation. [25] [26] [27] [28] Slowness determined by a 4-meter gait speed (<0.8 m/s) is a wellaccepted, validated, and sensitive cutoff for frailty screening in older communitydwelling adults and has been reported to be associated with poor functional capacity and self-efficacy in patients with COPD. 29 A 10-second cutoff on the Timed Up and Go test and a score of 3 or more on the PRISMA-7 (Program of Research to Integrate Services for the Maintenance of Autonomy) questionnaire are also sensitive in screening for frailty. 29 Practical Implications Recognition of frailty should direct clinicians to place greater efforts in counseling and referring these patients to pulmonary rehabilitation, including nonehospital-based programs to provide the greatest chance for participant retention and ongoing benefits after program completion. We recommend proactive screening for frailty in patients with COPD, particularly in the elderly.
EMOTIONAL FRAILTY PHENOTYPE
Emotional frailty, an increasingly recognized phenotype in COPD, merits recognition because of its substantial and independent impact on outcomes and implications for management. The characteristics of emotional frailty in patients with COPDdanxiety, depression, and fear of breathlessnessdare associated with a well-documented increase in morbidity, mortality, hospitalizations, duration of hospital stay, and readmissions and can aid in its recognition. 16, 30, 31 Emotional frailty in COPD likely develops because of the complex interactions between the external and internal milieu of the patients and their diseasedpersonality type, emotional intelligence, coping style, psychosocial support and stressors, biological changes induced by disease, and the severity and manifestations of the COPD itself and other comorbidities (Figure 2) . Emotional intelligence and coping are intricately linked and substantially impact depression, anxiety, and self-management in COPD. 32, 33 Conversely, a sense of coherence, resiliency, illness acceptance, and the presence of a social support system negatively correlate with anxiety and depression. Fear of breathlessness identified by the question, "How often during the past 2 weeks did you have a feeling of fear or panic when you had difficulty getting your breath?" has been independently associated with hospitalizations. 34 A score of more than 3 on either the Patient Health Questionnaire-2, a depression screening tool, or the Generalized Anxiety Disorder-2 scale could also be used to screen patients with COPD for emotional frailty.
Although anxiety and depression must be considered and treated in patients with COPD, the efficacy of pharmacological treatment does not seem particularly encouraging or well defined at this time. 35 The role of cognitive behavioral therapy is plausible, but robust data regarding efficacy and effect size are lacking. 35, 36 Pulmonary rehabilitation by itself, and more so in conjunction with more comprehensive programs that include education, psychosocial support, and other behavioral and self-management techniques, appears to equal or supersede the effects seen with pharmacological therapy alone for anxiety and depression in COPD. 37, 38 Health coaching has recently been reported to be effective for improvement of the emotional domain in COPD in a large randomized study of patients with severe COPD discharged after an exacerbation.
Practical Implications
Patients with COPD who have emotional frailtydthose with anxiety, depressive symptoms, or fear of breathlessnessdare at high risk for adverse health outcomes. They must be proactively identified and enrolled in comprehensive pulmonary rehabilitation programs that include health coaching or cognitive behavioral therapy to address emotional frailty along with physical rehabilitation.
LIMITATIONS
We are aware that the list of proposed phenotypes is likely incomplete and possibly arbitrary.
We also acknowledge that an overlap between the described phenotypes is likely common in clinical practice because these phenotypes were distinguished by their common characteristics, prognostic importance, and outcomes, not defined along rigid boundaries of anatomic, physiologic, or pathologic criteria. Inclusion into one phenotype, therefore, is not to the exclusion of the others.
CONCLUSION
We have attempted to describe clinically meaningful COPD phenotypes that should be easily identifiable by primary care physicians as well as specialists. We recommend that patients in the primary care clinic who are challenging from a diagnostic or management perspective or require specialized evaluation (eg, for transplant) be referred to a specialist. We hope that the recognition of these phenotypic characteristics will help guide personalized and effective care for patients with COPD and positively impact their quality of life as well as health care utilization outcomes. 
